학술논문
Initial Guidance on Use of Monoclonal Antibody Therapy for Treatment of Coronavirus Disease 2019 in Children and Adolescents.
Document Type
Article
Author
Wolf, Joshua; Abzug, Mark J; Wattier, Rachel L; Sue, Paul K; Vora, Surabhi B; Zachariah, Philip; Dulek, Daniel E; Waghmare, Alpana; Olivero, Rosemary; Downes, Kevin J; James, Scott H; Pinninti, Swetha G; Yarbrough, April; Aldrich, Margaret L; MacBrayne, Christine E; Soma, Vijaya L; Grapentine, Steven P; Oliveira, Carlos R; Hayes, Molly; Kimberlin, David W; Jones, Sarah B; Bio, Laura L; Morton, Theodore H; Hankins, Jane S; Maron, Gabriela M; Timberlake, Kathryn; Young, Jennifer L; Orscheln, Rachel C; Schwenk, Hayden T; Goldman, David L; Groves, Helen E; Huskins, W Charles; Rajapakse, Nipunie S; Lamb, Gabriella S; Tribble, Alison C; Lloyd, Elizabeth C; Hersh, Adam L; Thorell, Emily A; Ratner, Adam J; Chiotos, Kathleen; Nakamura, Mari M
Source
Journal of the Pediatric Infectious Diseases Society; May 2021, Vol. 10 Issue: 5 p629-634, 6p
Subject
Language
ISSN
20487193; 20487207
Abstract
In November 2020, the US Food and Drug Administration (FDA) provided Emergency Use Authorizations (EUA) for 2 novel virus-neutralizing monoclonal antibody therapies, bamlanivimab and REGN-COV2 (casirivimab plus imdevimab), for the treatment of mild to moderate coronavirus disease 2019 (COVID-19) in adolescents and adults in specified high-risk groups. This has challenged clinicians to determine the best approach to use of these products.